Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer.

Trial Profile

Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2014

At a glance

  • Drugs OPB 51602 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record
    • 11 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top